Search

everythinglearnresearchcommunity

for

Search:↓

Some men experience persistent sexual, neurological, and psychological symptoms after stopping finasteride, but evidence of permanent damage is inconclusive.

The ARTAS robotic system for hair restoration is efficient with fewer cuts than manual methods, but it's limited to certain hair types and can still leave scars.

The new FDA labeling rules provide more detailed drug safety information for pregnant and breastfeeding women, but more data is needed on the risks of many dermatologic drugs.

Different countries have regulations to ensure the safety of hair care products, with some recalling hair straighteners due to high formaldehyde.

Many treatments for hair loss lack proper testing and FDA approval, so their effectiveness is uncertain.

Cepharanthine, a Japanese hair loss drug, shows promise as a COVID-19 treatment but needs more testing.

PRP treatments for hair loss need standard protocols to be reliable.

Off-label treatments are heavily used for alopecia areata due to limited approved options.

The FDA rejected a testosterone drug again due to safety concerns.

JAK/STAT inhibitors show promise for skin diseases but aren't yet approved.

Minoxidil helps treat pattern hair loss in both men and women.

New treatments for hair loss show promise, especially finasteride for men and a stronger minoxidil formula.

Medicaid coverage for alopecia areata treatments is inconsistent and often limited.

Dutasteride is more effective than finasteride for hair loss, but more research is needed on safety and dosing.

Testosterone therapy can improve sexual desire and function in postmenopausal women but should be used cautiously and not based solely on testosterone levels.

Testosterone treatment can improve sexual function and bone density in women but may have adverse effects and requires more research on safety and guidelines.

The document concludes that there are various treatments for different types of alopecia, but more research is needed for evidence-based treatments.

The Polish Society of Dermatology recommends treatments for alopecia areata that vary by severity, including topical and systemic medications, with long-term maintenance important for management.

Rimegepant causes more nausea and skin issues, while ubrogepant causes more muscle issues; personalized treatment is important.

New drugs and combination therapies are improving treatment for lower urinary tract symptoms.

New treatments for hair loss are emerging, and doctors need to learn how to use them effectively.

The AA-IGA scale reliably measures treatment success in alopecia areata by considering both clinician and patient views.

Effective delivery systems are crucial for siRNA hair loss treatments to work better.

Alopecia Areata affects 2% globally, with treatments like essential oils, garlic, and JAK inhibitors showing promise, but more research is needed.

Low-level laser therapy is the most effective for hair loss, but other treatments also show promise.

Low-dose finasteride may cause lasting sexual dysfunction and suicidal thoughts in young men.

Hydroxychloroquine and chloroquine are not recommended for COVID-19 treatment due to insufficient evidence and safety concerns.

Ritlecitinib provides new treatment options for diverse alopecia areata patients.

Six African American women experienced hair loss after switching to a new HIV medication.

Finasteride's effectiveness on the frontal hair loss area is not well-studied or confirmed.